Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

Y0001522

Anastrozole

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

2;2"-[5-(1H-1;2;4-Triazol-1-ylmethyl)-1, 3-Phenylene]bis(2-methyl-propiononitrile, Arimidex, ICI-D1033, ZD1033, a,a,a′,a′-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile

Sign Into View Organizational & Contract Pricing

Select a Size

100 MG
$164.00

$164.00

Available to ship onMay 01, 2025Details

Request a Bulk Order
All Photos(1)

Select a Size

Change View
100 MG
$164.00

About This Item

Empirical Formula (Hill Notation):
C17H19N5
CAS Number:
120511-73-1
Molecular Weight:
293.37
UNSPSC Code:
41116107
NACRES:
NA.24

$164.00

Available to ship onMay 01, 2025Details

Request a Bulk Order

grade

pharmaceutical primary standard

API family

anastrozole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[n]2(ncnc2)Cc1cc(cc(c1)C(C)(C)C#N)C(C)(C)C#N

InChI

1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3

InChI key

YBBLVLTVTVSKRW-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Anastrozole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Anastrozole is a nonsteroidal aromatase inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Catherine M Kelly et al.
Expert opinion on drug safety, 9(6), 995-1003 (2010-10-07)
Anastrozole is a third-generation aromatase inhibitor used in the adjuvant setting for the treatment of hormone receptor-positive breast cancer. Several adjuvant randomized trials have reported greater efficacy for anastrozole when compared to tamoxifen. This review discusses the mechanism of action
Peter H Graham
Expert opinion on pharmacotherapy, 8(14), 2347-2357 (2007-10-12)
Anastrozole is a third-generation aromatase inhibitor with an extensive evidence base to preferentially support its use in multiple scenarios in endocrine-responsive breast cancer. These include neoadjuvant treatment, immediate and delayed adjuvant treatment, salvage treatment and first-line treatment of advanced breast
Robert W Carlson et al.
Breast cancer research and treatment, 80 Suppl 1, S19-S26 (2003-10-11)
The use of adjuvant endocrine therapy in the treatment of hormone receptor-positive, early breast cancer has become important in both pre- and postmenopausal women. Tamoxifen has been the principal adjuvant hormonal therapy in pre- and postmenopausal women with hormone receptor-positive
Mark Sanford et al.
Drugs, 68(9), 1319-1340 (2008-06-13)
Anastrozole (Arimidex) is an aromatase inhibitor approved in the EU, the US and in other countries worldwide for use as an adjuvant treatment in postmenopausal women with early-stage, hormone receptor-positive breast cancer. It is also approved in the EU and
Jennifer L Lycette et al.
Breast cancer research and treatment, 99(3), 249-255 (2006-06-06)
Hormonal therapy is the mainstay of adjuvant treatment for women with early-stage estrogen receptor-positive breast cancer. Recently, the aromatase inhibitors have moved to the forefront of adjuvant hormonal therapy, however, the adverse effects of these agents are not yet fully
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service